Loading
A US study testing two experimental multi-cancer tests, one on blood and urine sugars and one on blood proteins, in firefighters.
Multi-cancer early detection in firefighters (NCT05780957) is an observational study sponsored by Vincere Cancer Center with Elypta, Proteotype. Its primary outcomes are sensitivity, specificity and predictive values of Elypta's test in plasma, urine and both, and of Proteotype's protein test in plasma.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 2,000 participants, a start on 21 March 2023 and primary completion expected on 31 December 2026.
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Elypta GAGome multi-cancer test, Elypta, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/